We read the recent study by Niemann et al. (2022) [...].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600176 | PMC |
| http://dx.doi.org/10.3390/diagnostics12102343 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Arimoclomol: First Approval.
Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Arimoclomol (MIPLYFFA™), an oral small molecule that crosses the blood brain barrier and is thought to upregulate CLEAR (Coordinated Lysosomal Expression and Regulation) network genes and improve lysosomal function, is being developed by Zevra Therapeutics Inc., for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC). In September 2024, arimoclomol was approved for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients 2 years of age and older in the USA.
View Article and Find Full Text PDFA composite reference standard is needed for bedaquiline antimicrobial susceptibility testing for complex.
Eur Respir J
July 2024
Department of Infectious Diseases, Region Östergötland, Linköping University Hospital, Linköping, Sweden.
https://bit.ly/3wAVvFm
View Article and Find Full Text PDFRe: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al.
Clin Microbiol Infect
September 2024
Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!